Custom AAV Buffers: Give Your AAV Therapeutic A Boost

By Brad N. Taylor, Ph.D.

AAV (adeno-associated virus)-mediated therapies are paving the way for groundbreaking treatments. In 2023, two AAV gene therapies earned FDA approval for hemophilia A and muscular dystrophy, highlighting their potential. However, the journey from development to approval isn't without its hurdles. Variability in viral titer, transduction efficiency, and purification can slow progress. This is where custom buffer formulation comes into play.

Optimizing biological buffers early in the process not only stabilizes AAV vectors but also mitigates manufacturing challenges, ensuring purity and scalability. Custom buffers can streamline downstream processes, reduce contamination risks, and help navigate complex regulatory requirements.

Learn how flexible, GMP-compliant buffer solutions are designed to streamline your AAV gene therapy pipeline, from early-stage research to clinical trials. Access the full article to for further insights into explore how custom buffers can help AAV therapeutics reach the market faster.